Stella Diagnostics (Stella Diagnostics) Other Income (Expense) : $ Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Other Income (Expense)?

Stella Diagnostics's other income expense for the Stella Diagnostics's pretax income for the three months ended in Sep. 2023 was $-0.38 Mil.

Stella Diagnostics Other Income (Expense) Historical Data

The historical data trend for Stella Diagnostics's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Other Income (Expense) Chart

Stella Diagnostics Annual Data

Trend

Other Income (Expense)

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Other Income (Expense)	-0.15	-0.38

Stella Diagnostics Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Stella Diagnostics (OTCPK:SLDX) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.